Fig. 6: Context-dependent effect of BA.5, BA.2.75, and BA.2.75.2 substitutions on broadly neutralizing antibody sensitivity.
From: Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape
a Naturally occurring Receptor-Binding Domain (RBD) substitutions in a selection of BA.1, BA.2, and BA.5 derived SARS-CoV-2 variants. Positions marked with asterisks indicate those at which substitutions arose during broadly neutralizing antibody selection experiments. b Inhibition of Wuhan-Hu-1 and BA.2 RBD pseudotypes with L452R or F486S substitutions by broadly neutralizing antibodies, in comparison with BA.5. c Inhibition of Wuhan-Hu-1 and BA.2 RBD pseudotypes with R346W, G446N, or N460K substitutions by broadly neutralizing antibodies, in comparison with BA.2.75 and BA.2.75.2. b, c Relative infection is defined as the decimal fraction of infection measured (with 1 μg/ml antibody), relative to an uninhibited virus control (without antibody) and median values from two independent experiments are displayed.
